| ID | 10113 |
| Vaccine Name | Imovax Rabies(Post exposure) |
| Disease Name | Rabies |
| Disease Classification | Neurologic |
| Virus Name | Rabies virus |
| Nucleic Acid Content | negative-sense, single-stranded RNA |
| Vaccine Type | Inactivated |
| Vaccine Status | Approved |
| Manufacturer | Sanofi Pasteur |
| Year of Manufacturing | 2005 |
| Manufacturing Country | France |
| Age | All age group |
| Dosage | 5 doses on day 0, 3, 7, 14 and 28 |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | WISTAR Rabies PM/WI38-1503-3M strain |
| Description | Human diploid cell vaccine |
| Approving Organisation | US FDA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | NA |
| PMID | NA |
| Clinical Trial ID | NA |
| Reference Link | https://www.cdc.gov/vaccines/vpd/rabies/hcp/index.html#ref |
| Additional Links | https://www.fda.gov/vaccines-blood-biologics/vaccines/imovax
|